CSL’s Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrated Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment
| | | |

CSL’s Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrated Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment

On Dec. 10, 2022, CSL announced data affirming the long-term durability and safety of single-infusion HEMGENIX® (etranacogene dezaparvovec-drlb)…

Seqirus’ Next Generation Cell-based Influenza Vaccine Shows Significantly Greater Effectiveness Compared to Standard Egg-based Options in the 2017-18 US Influenza Season
| | | |

Seqirus’ Next Generation Cell-based Influenza Vaccine Shows Significantly Greater Effectiveness Compared to Standard Egg-based Options in the 2017-18 US Influenza Season

On Dec. 5, 2018, Seqirus, a CSL subsidiary, announced real-world data showing that its cell-based quadrivalent influenza vaccine…